Christopher Benecchi - Feb 3, 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Chief Business Officer
Signature
/s/ Anne Marie Cook, as Attorney-in-Fact for Christopher Benecchi
Stock symbol
SAGE
Transactions as of
Feb 3, 2023
Transactions value $
-$93,575
Form type
4
Date filed
2/7/2023, 03:10 PM
Previous filing
Jun 21, 2022
Next filing
Feb 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +6.75K +1073.13% $0.00 7.38K Feb 3, 2023 Direct F1, F2
transaction SAGE Common Stock Tax liability -$93.6K -2.12K -28.72% $44.16 5.26K Feb 3, 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On October 1, 2021, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 22,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on February 3, 2023, resulting in the vesting of the PSUs as to 6,750 shares.
F2 Reflects beneficial ownership balance which includes 414 shares purchased on June 30, 2022 and 215 shares purchased on December 31, 2022, each under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.